66 results about "CD146" patented technology

In one embodiment, the invention provides a pericyte having a marker pattern comprising CD146+, CD34−, and CD45−, wherein said pericyte is substantially isolated from cells that are CD146− or CD31+ or CD34+ or CD45+ or CD56+ or NG2− or CD133−. The invention also provides populations of such pericytes. In another embodiment, the invention provides a method for isolating a pericyte. In another embodiment, the invention provides a method for modeling tissue in vivo.

The invention provides therapeutic or diagnostic antibodies with modified N— or C-terminal sequences that are enriched with lysine or tyrosine residues. These lysine or tyfosine residues can be used to couple radioisotopes, cytotoxic agents, or detectable labels. The increased stoichiometric ratios of these agents in the antibody conjugates lead to improved therapeutic efficacy or enhanced detection sensitivity. Non-limiting examples of antibodies suitable for the present invention include anti-CD22, anti-ErbB2, anti-VEGF, anti-EGFR, anti-VEGFR, anti-Her-3, anti-Her-4, anti-CEA, anti-CTLA-4, anti-CD4, anti-CD3, anti-CD20, anti-TNF-a, anti-CD11a, anti-Lewis Y antigen, anti-TrailR, anti-IL2R, anti-CD30, anti-CD146, anti-CD147, anti-alpha V integrin beta, anti-CD19, anti-GD2, anti-3H11, anti-EBV, anti-HIV, anti-HBV, anti-HCV, and other disease-specific antibodies.

The invention relates to a group of anti-human CD146 molecules which are developed by utilizing the biological technology and an established high-sensitive sandwich ELISA method for detecting the solubility CD146. The invention includes anti-human CD146 mouse monoclonal antibodies of AA1, AA2, AA3, AA4, AA5 and AA7, and the method of utilizing the combination of the antibodies and the sandwich ELISA specificity for detecting the solubility CD146. The group of antibodies can identify the human source CD146 on the molecular, the cellular and the tissue levels, which can be divided into two categories based on the identified different epitopes. The sandwich ELISA method which is combined by the antibody AA1 and another strain of anti-human CD146 mouse monoclonal antibody AA98 can detect the solubility CD146 at each milliliter nano-gram level. The antibodies and the detection means can become the effective detection or diagnosis tools and method in the basic research or the clinical application and provide good carriers for the targeted therapy of the CD146-related diseases at the same time.

The present invention relates to a method for diagnosing cancer in a subject said method comprising the steps of providing a biological sample from a subject, and determining the expression of the MCAM gene in a circulating tumor cell (CTC) in said biological sample.

A method of distinguishing mesenchymal stem cells (MSCs) from fibroblasts is provided. Also provided is a method of increasing a purity of mesenchymal stem cells (MSCs) population in a cell culture. The above-mentioned methods each comprise a step of sorting or isolating the cells by a marker of CD146 from a cell culture derived from a placenta-related tissue. Further provided is a method of assessing purity of mesenchymal stem cells (MSCs) in a cell culture derived from a placenta-related tissue, comprising determining the percentage of cells expressing CD146 in the culture.

An application of a CD146 monoclonal antibody in detection and separation and identification of glioma perivascular cells. The CD146 monoclonal antibody is prepared from a hybridoma cell strain which is assigned the accession number of CCTCC No: C2016183. The CD146 monoclonal antibody 4F10 has excellent specificity and can accurately recognize tumor perivascular cells. In addition, the CD146 monoclonal antibody 4F10 can be used for flow cytometry sorting and detection of glioma-derived pericytes.

A method for detecting CD146 molecule includes utilizing protein chip and optical oval polarization microscope imaging technique to prepare CD146 antibody optical chip being used to detect CD146 content in body liquid of patient, utilizing stream cell technique to detect CD146 presentation state on white blood cell of patient.

The present invention provides a compound CaP/PEI/poly(I:C)/SiO2-S-Ab containing cell targeting antibodies and Poly(I:C), wherein the compound uses calcium phosphate nanoparticles as the core, the surface of the core is grafted with PEI, the Poly(I:C) is adsorbed and loaded on the surface of the core, the outer portion of the core is a silica shell, and the silica shell is linked to four differentcell targeting antibodies (such as CD146 antibody targeting liver sinusoidal endothelial cells, F4/80 antibody targeting kupffer cells, IgG1 isotype control antibody targeting IgG1 antibody expression Fc receptor cells, and IgG2 isotype control antibody targeting IgG2 antibody expression Fc receptor cells). The invention further provides a preparation method and medical uses of the compound. According to the present invention, with the compound, the poly(I:C) can reach the intrahepatic cells in the targeted manner so as to bind the poly(I:C) to TLR3, such that the generation of interferons and proinflammatory cytokines can be enhanced by activating different immune cell TLR3-mediated signaling pathways so as to provide the anti-HBV virus effect.

The invention relates to CD146 and antibody diagnosis thereof, and an application thereof in treating triple negative breast cancers. For a first time, the invention provides that CD146 is a novel target of triple negative breast cancer, and an anti-CD146 antibody might become a novel targeting medicine for treating the disease. Therefore, the invention provides an application of CD146 or anti-CD146 antibody or a functional form of the antibody in preparing medicines used for diagnosing and/or treating triple negative breast cancers. CD146 molecules are subjected to specific high expression in triple negative breast cancer tissues, and induce the occurrences of transformation of epithelial cell to mesenchymal cell in tumor cells. Therefore, tumor invasion migration is promoted. Therefore, the mechanism for CD146 antibody to treat triple negative breast cancer is mainly that the CD146 antibody inhibits the mesenchymal cell characteristics of triple negative breast cancer, and reduces the metastasis invasion capacity thereof. Compared with common chemotherapy medicines, the anti-CD146 antibody has the advantages of low side effects and clear target. The anti-CD146 antibody does not cause whole-body side effect.

The invention discloses a kit, a system and a method for determining patient marrow microenvironment after hematopoietic stem cell transplantation, wherein the applications of the kit, the system and the method are based on a flow cytometer, and the following fluorescently-labeled monoclonal antibody reagents are arranged in the kit: CD34-FITC, CD146-PE, CD45-PerCP and CD133-APC. The system comprises a main control computer unit, and a storage unit for storing empirical data and diagram, and the configuration of the hardware is an important guarantee for implementing determination. An expression proportion of a CD45-CD34-CD146+ cell in a bone marrow mononuclear cell is firstly used as an index for evaluating the quality of the marrow microenvironment of a blood disease patient after hematopoietic stem cell transplantation, has guiding significance for predicting generation of transplantation badness of the blood disease patient after hematopoietic stem cell transplantation, and has important reference value for guidance of making a clinic treatment scheme for a transplantation badness patient.

The invention discloses a kit for verifying endodontium mesenchymal stem cells. The kit comprises a flow phenotype detection reagent set, cell fixation liquid, an ordinary culture medium, an adipogenesis induction and detection reagent set, an osteogenesis induction and detection reagent set and a chondrogenesis induction and detection reagent set. Usually, conventional osteogenesis induction and adipogenesis induction need about 24 days, consumed time is long, and induction efficiency is low; by the kit, the time for osteogenesis induction and adipogenesis induction is shortened to 18 days, induction efficiency is improved, and induction time is shortened; conventional flow detection mainly aims at universal surface markers of mesenchymal stem cells, but the endodontium mesenchymal stem cells have positively-expressed surface markers CD146 which are different from the surface markers of other mesenchymal stem cells; CD146 antibodies are added into the kit, and accordingly, accurate verification results can be acquired.

The present invention discloses a human endometriosis cell, EM 257, which has been stored in the food industry research and development institute. Results obtained from a flow cytometry reveal that the human endometriosis cell of the present invention is positive for the mesnchymal stem cell surface antigens, such as CD44, CD73, CD105 and CD146. In different differentiation conditions, the human endometriosis cell of the present invention can be differentiated into osteogenic or adipogenic lineage cells.

A pharmaceutical composition for the prevention or treatment of a pulmonary disorder is provided. The composition contains mesenchymal stem cells showing improved proliferation and differentiation capacity which are characterized by the expression or non-expression of one or more particular cell markers. Also, provided is a method for obtaining mesenchymal stem cells showing improved proliferation and differentiation capacity based on the expression or non-expression of such cell markers. The mesenchymal stem cells having improved proliferation and differentiation capacity can be easily obtained from mesenchymal stem cells of various origins based on the expression or non-expression of CD26, CD49f, CD146 and EGFR. The mesenchymal stem cells thus obtained can be effectively used for the prevention or treatment of a pulmonary disorder such as, for example, pulmonary emphysema.

Methods for targeted breast cancer therapy in a subject based upon evaluating the stromal subtypes and CD146 composition in the adjacent tissue. ER+ breast cancers contain two CAF subtypes defined by CD146 expression. CD146^neg CAFs suppress ER expression in ER+ breast cancer cells, decrease tumor cell sensitivity to estrogen, switch ER proliferation dependency toward EGFR dependency and decrease tumor cell sensitivity to antiendocrine therapy. Conversely, the presence of CD146P^pos CAFs enhances ER expression in ER+ breast cancer cells and sustains ER-dependent proliferation and sensitivity to tamoxifen. Co-cultures of CD146^pos CAFs with tamoxifen-resistant breast cancer cells restores sensitivity to tamoxifen. Gene expression profiles of patient breast tumors with predominantly CD146^neg CAFs correlate with inferior clinical response to tamoxifen and worse patient outcomes. CAF composition contributes to treatment response and patient outcomes in ER+ breast cancer, and provide a target for drug development.

The invention discloses an application of CD146 as a treatment target point to preparation of medicines for treating asthma airway remodeling, an application of the CD146 as the treatment target pointto screening and treating asthma, an application of substances for restraining CD146 expression or antagonism CD146 to preparation of medicines for treating bronchial asthma, and preferably, an application of preparation of medicines for asthma airway remodeling. The invention discloses an application of the CD146 for detecting plasma of patients suffering from bronchitis. For the first time, theinventor finds expression differences of the CD146 in serum of patients suffering from asthma and serum of normal people. The indexes can be used as a serum molecule marker for the bronchial asthma.The research indicates that HDM can worsen the airway remodeling through the CD146. Therefore, the CD146 can be used as the treatment target point to be used for screening and treating bronchial asthma. In accordance with an antibody of the CD146, the CD146 is also a treatment strategy for the bronchial asthma.

The invention provides application of a CD146 + mesenchymal stem cell subset in preparation of a medicine for preventing and treating premature ovarian failure, and belongs to the technical field of biological medicines. The invention provides an application of a CD146 + mesenchymal stem cell subset in preparation of a medicine for preventing and treating premature ovarian failure. The treatment efficiency of the CD146 + MSCs and the treatment efficiency of the CD146-MSCs on a mouse POF model are compared, compared with a model group, the MSCs remarkably improve the premature ovarian failure, and the CD146 + subgroup has a slightly good trend compared with the CD146-MSCs. Meanwhile, the invention also provides an application of the CD146 + mesenchymal stem cell subset in preparation of a medicine for improving the immunoregulation ability of a premature ovarian failure patient. Experiments show that the CD146 + mesenchymal stem cell subgroup can significantly reduce the expression level of chemotactic factors and inflammatory genes and inhibit T cell proliferation, which indicates that the CD146 + subgroup has better immunoregulation ability.

The invention relates to application of soluble CD146 protein in cerebrospinal fluid to preparation of a kit or a diagnostic agent for differential diagnosis, course judgment and/or medication guidance of individual inflammatory central nervous system diseases and the prepared kit or diagnostic agent. The application and the kit or the diagnostic agent have good sensitivity, accuracy, stability and operability.

The invention discloses a tumor perivascular cell as well as a separation method and application thereof, and belongs to the technical field of biology. The method provided by the invention comprises the steps: stripping a fresh solid tumor tissue sample to obtain tumor blood vessels, cutting the tumor blood vessels into annular segments, then putting the tumor blood vessels of the annular segments into a pore plate pre-paved with matrigel, culturing by using a perivascular cell culture medium, and finally recovering the tumor perivascular cells from the matrigel. The tumor perivascular cells provided by the invention highly express four positive molecular markers of FAP[alpha], NG2, PDGFR[beta] and CD146, and do not express two negative molecular markers of CD31 and MYH11. By utilizing the tumor perivascular cells, a breakthrough of zero construction of an immortalized human colorectal cancer perivascular cell model is realized. The invention can provide an original material with reliable source, sufficient quantity and stable quality for researching biological functions and drug targets of solid tumor perivascular cells, and has a wide application prospect.